Rotavirus is a leading cause of severe pediatric diarrhea globally, estimated to have caused 120,000 deaths among children aged \<5 years in sub-Saharan Africa in 2013 ([@R1]). In 2009, the World Health Organization (WHO) recommended rotavirus vaccination for all infants worldwide ([@R2]). Two rotavirus vaccines are currently licensed globally: the monovalent Rotarix vaccine (RV1, GlaxoSmithKline; 2-dose series) and the pentavalent RotaTeq vaccine (RV5, Merck; 3-dose series). This report describes progress of rotavirus vaccine introduction ([@R3]), coverage (using estimates from WHO and the United Nations Children's Fund \[UNICEF\]) ([@R4]), and impact on pediatric diarrhea hospitalizations in the WHO African Region. By December 2016, 31 (66%) of 47 countries in the WHO African Region had introduced rotavirus vaccine, including 26 that introduced RV1 and five that introduced RV5. Among these countries, rotavirus vaccination coverage (completed series) was 77%, according to WHO/UNICEF population-weighted estimates. In 12 countries with surveillance data available before and after vaccine introduction, the proportion of pediatric diarrhea hospitalizations that were rotavirus-positive declined 33%, from 39% preintroduction to 26% following rotavirus vaccine introduction. These results support introduction of rotavirus vaccine in the remaining countries in the region and continuation of rotavirus surveillance to monitor impact.

The status of rotavirus vaccine introduction and 2016 WHO/UNICEF estimates of national vaccination coverage were obtained from the WHO repository ([@R3],[@R4]). Among African Region countries that have introduced rotavirus vaccine into their national Expanded Programs on Immunization, most recommend that rotavirus doses coincide with administration of the infant doses of diphtheria and tetanus toxoids and pertussis (DTP) vaccine (at ages 6 and 10 weeks for RV1 and at ages 6, 10, and 14 weeks for RV5); most countries are using RV1 ([@R5]). Because the WHO/UNICEF estimates do not include a coverage estimate for the first dose of rotavirus vaccine or the second dose of DTP vaccine, rotavirus vaccination coverage (completed series of either 2 RV1 or 3 RV5 doses) was compared with first-dose and third-dose coverage for DTP. Countries that have introduced rotavirus vaccine were grouped by year of vaccine introduction for analysis.

Rotavirus surveillance data were collected through sentinel hospitals participating in the African Rotavirus Surveillance Network (ARSN), which was established in four countries in 2006 and had expanded to 29 countries by 2016 ([Figure](#F1){ref-type="fig"}) ([@R6]). Surveillance staff members at sentinel sites in ARSN enroll children aged \<5 years who are hospitalized for acute diarrhea (≥3 looser than normal stools in a 24-hour period before hospitalization, with duration of illness ≤7 days before hospitalization) and collect a stool specimen, which is tested for rotavirus using an enzyme immunoassay. Countries were included in this analysis if their sites collected and tested at least 80 specimens over at least 11 months in a given year. The percentage of tested specimens that were positive for rotavirus was calculated in the vaccine preintroduction and postintroduction periods, by country. The year of rotavirus vaccine introduction was considered a transition period and was excluded from calculations.
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Overall, 31 (66%) countries in the region had introduced rotavirus vaccine into their national immunization schedules by December 2016, with 26 introducing RV1 and five introducing RV5 ([Table 1](#T1){ref-type="table"}). Among all countries, completed series rotavirus vaccination coverage was 77% (population-weighted average); national coverage ranged from 24% (Sao Tome and Principe, 2016 introduction) to 98% (Rwanda, 2012 introduction). When grouping by year of vaccine introduction, the highest overall population-weighted coverage (82%) was in countries that introduced the vaccine before 2014. These same countries also had the smallest average percentage-point difference between completed rotavirus vaccination coverage and DTP1 coverage (overall, 11 percentage points less than DTP1).

###### Percentage coverage with first and third DTP vaccine doses and completed rotavirus (RV) vaccination series --- World Health Organization African Region, 2016

  Country                                             Year RV vaccine introduced   RV vaccine type   Coverage (%)   Percentage-point difference in coverage                     
  --------------------------------------------------- ---------------------------- ----------------- -------------- ----------------------------------------- -------- -------- -------
  **Countries introducing RV vaccine 2009--2013\***   **---**                      **---**           **93**         **88**                                    **82**   **11**   **6**
  South Africa                                        2009                         RV1               78             66                                        73       5        −7
  Botswana                                            2012                         RV1               98             95                                        95       3        0
  Ghana                                               2012                         RV1               94             93                                        94       0        −1
  Malawi                                              2012                         RV1               89             84                                        81       8        3
  Rwanda^†^                                           2012                         RV5               99             98                                        98       1        0
  Tanzania                                            2012                         RV1               99             97                                        96       3        1
  Burkina Faso                                        2013                         RV5               95             91                                        91       4        0
  Burundi                                             2013                         RV1               97             94                                        96       1        −2
  Ethiopia                                            2013                         RV1               86             77                                        63       23       14
  Gambia^†^                                           2013                         RV5               99             95                                        95       4        0
  Zambia                                              2013                         RV1               99             91                                        90       9        1
  **Countries introducing RV vaccine 2014\***         **---**                      **---**           **89**         **79**                                    **73**   **16**   **6**
  Angola                                              2014                         RV1               79             64                                        53       26       11
  Cameroon                                            2014                         RV1               92             85                                        80       12       5
  Republic of the Congo                               2014                         RV1               85             80                                        80       5        0
  Eritrea                                             2014                         RV1               97             95                                        96       1        −1
  Kenya                                               2014                         RV1               96             89                                        74       22       15
  Madagascar                                          2014                         RV1               84             77                                        78       6        −1
  Mali                                                2014                         RV5               86             68                                        60       26       8
  Mauritania                                          2014                         RV1               87             73                                        73       14       0
  Namibia                                             2014                         RV1               98             92                                        86       12       6
  Niger                                               2014                         RV1               87             67                                        61       26       6
  Senegal                                             2014                         RV1               96             93                                        93       3        0
  Sierra Leone                                        2014                         RV1               97             84                                        95       2        −11
  Togo                                                2014                         RV1               93             89                                        90       3        −1
  Zimbabwe                                            2014                         RV1               94             90                                        91       3        −1
  **Countries introducing RV vaccine 2015--2016\***   **---**                      **---**           **92**         **81**                                    **73**   **19**   **8**
  Guinea-Bissau                                       2015                         RV1               95             87                                        61       34       26
  Mauritius                                           2015                         RV1               97             96                                        92       5        4
  Mozambique                                          2015                         RV1               90             80                                        76       14       4
  Swaziland                                           2015                         RV1               96             90                                        95       1        −5
  Liberia                                             2016                         RV1               99             79                                        48       51       31
  Sao Tome and Principe                               2016                         RV5               97             96                                        24       73       72

**Abbreviations:** DTP = diphtheria and tetanus toxoids and pertussis; DTP1 = first dose of DTP vaccine; DTP3 = third dose of DTP vaccine; RV1 = monovalent RV vaccine (Rotarix); RV5 = pentavalent RV vaccine (RotaTeq).

\* Summary data for introduction period are population-weighted averages.

^†^ Country initially introduced RV5, but switched to RV1 in 2017.

Surveillance data were available for 12 and 18 countries during the vaccine preintroduction and postintroduction periods, respectively ([Table 2](#T2){ref-type="table"}). The average percentage of tested stool specimens that were positive for rotavirus during the vaccine preintroduction period was 41%, ranging from 20% (Ethiopia) to 51% (Togo). During the vaccine postintroduction period, the average percentage of rotavirus-positive specimens was 24%, ranging from 12% (Madagascar) to 41% (Mauritius). In the 12 countries with both vaccine preintroduction and postintroduction data, rotavirus positivity declined by 33% overall (range = 2%--62%), from 39% in the preintroduction period to 26% in the postintroduction period (p\<0.001); in these countries, the overall population-weighted 2016 completed rotavirus vaccination series coverage was 82%. In 2016, the overall percentage of positive rotavirus stool specimens was 26% in countries that had introduced the vaccine in 2015 or earlier, and 43% in countries that had not yet introduced the vaccine (p\<0.001).

###### Rotavirus (RV) stool specimen surveillance results, by country and vaccine introduction status --- World Health Organization African Region, 2008--2015

  Country                                Year RV vaccine introduced   Vaccine preintroduction period   Vaccine postintroduction period   \% decline in RV positivity\*                                        
  -------------------------------------- ---------------------------- -------------------------------- --------------------------------- ------------------------------- -------------- -------- ------------ -----
  **Countries introducing 2012--2013**   ---                          ---                              9,916                             3,685 (37)                        ---          20,389   5,544 (27)   27%
  Ghana                                  2012                         2008, 2010--2011                 2,374                             1,161 (49)                        2013--2016   1,494    405 (27)     45%
  Rwanda                                 2012                         2011                             240                               121 (50)                          2013--2015   2,237    447 (20)     60%
  Tanzania                               2012                         2009--2010                       852                               308 (36)                          2013--2016   8,615    2,186 (25)   30%
  Zambia                                 2012                         2007--2011                       4,519                             1,700 (38)                        2013--2016   5,227    1,700 (33)   14%
  Burkina Faso                           2013                         NS                               NS                                NS                                2014--2016   1,889    615 (33)     NS
  Ethiopia                               2013                         2008--2012                       1,931                             395 (20)                          2014--2016   822      165 (20)     2%
  Gambia                                 2013                         NS                               NS                                NS                                2014         105      26 (25)      NS
  **Countries introducing 2014**         ---                          ---                              14,062                            5,628 (40)                        ---          6,704    1,552 (23)   42%
  Angola                                 2014                         NS                               NS                                NS                                2015         229      41 (18)      NS
  Cameroon                               2014                         2008--2013                       3,449                             1,398 (41)                        2015--2016   973      197 (20)     50%
  Kenya                                  2014                         2007--2013                       4,406                             1546 (35)                         2015--2016   688      158 (23)     35%
  Madagascar                             2014                         NS                               NS                                NS                                2015--2016   451      56 (12)      NS
  Niger                                  2014                         NS                               NS                                NS                                2016         168      22 (13)      NS
  Senegal                                2014                         2011--2013                       374                               159 (43)                          2015--2016   235      38 (16)      62%
  Togo                                   2014                         2008, 2010--2013                 1,028                             526 (51)                          2015--2016   319      119 (37)     27%
  Zimbabwe                               2014                         2008--2009, 2011--2013           4,805                             1,999 (42)                        2015--2016   3,641    921 (25)     39%
  **Countries Introducing 2015**         ---                          ---                              1,319                             626 (47)                          ---          1,081    330 (31)     36%
  Mauritius                              2015                         2010--2014                       1,203                             578 (48)                          2016         570      235 (41)     14%
  Mozambique                             2015                         NS                               NS                                NS                                2016         420      68 (16)      NS
  Swaziland                              2015                         2013                             116                               48 (41)                           2016         91       27 (30)      28%

**Abbreviations:** NS = No surveillance data available (surveillance not started or data do not meet analysis criteria); RV = rotavirus vaccine.

\* Calculated only for countries with data on rotavirus vaccine preintroduction and postintroduction. Percentage declines might not correspond to preintroduction and postintroduction percentages because of rounding.

Discussion
==========

Countries in the WHO African Region have made significant progress in the introduction of rotavirus vaccines, with 31 (66%) of 47 member countries having introduced rotavirus vaccine into their national schedules by December 2016. In 2016, the overall completed series rotavirus vaccination coverage in these countries was 77%, which was lower than coverage for DTP1 and DTP3. Some of this difference might be attributable to challenges that are common to new vaccine introduction (e.g., it can take time for all vaccination clinics to have reliable cold chain space and a steady stock of a new vaccine). In addition, challenges specific to the recording and reporting of coverage for new vaccines include mid-year introductions, unavailability of updated data tools, and inadequate orientation of health workers on use of vaccine tally sheets. Another factor specific to rotavirus is the issue of age restrictions. Because of concerns about a potential increased risk for intussusception in older infants who receive the vaccine, WHO initially recommended that rotavirus vaccination be administered only to children aged ≤32 weeks ([@R2]). In 2013, WHO recommended lifting these restrictions based on new data and a risk-benefit analysis ([@R7]); however, some countries, or some health workers, might still be administering rotavirus vaccine with age restrictions. Additional research is needed to better understand the impact of lifting age restrictions on coverage, and the difference between rotavirus and DTP vaccination coverage.

Surveillance data from ARSN indicate that, among countries with data available both preceding and following rotavirus vaccine introduction, the proportion of rotavirus-positive hospitalizations for diarrhea among children aged \<5 years declined 33% following rotavirus vaccine introduction; overall declines were especially notable in countries that had introduced rotavirus vaccine before 2015. These results are particularly encouraging given rotavirus vaccines' lower efficacy in low-income settings (50%--64% efficacy) than in high-income and middle-income settings (85%--100% efficacy) ([@R8]), which had raised concerns about the public health impact of their introduction. However, consistent with recent global analyses demonstrating substantial rotavirus vaccine impact across country income strata ([@R9]), the present analysis suggests that rotavirus vaccination has had a meaningful impact on rotavirus disease in Africa.

Sixteen countries in the WHO African Region had not yet introduced rotavirus vaccine as of December 2016; 10 are eligible for Gavi financial support, four of which have received approval. Apart from funding, other factors can affect rotavirus vaccine introduction and subsequent coverage. Coverage with routinely recommended vaccines, as a marker of immunization system function, highlights several countries in the region where the immunization infrastructure needs strengthening. Armed conflict and natural disasters, experienced by several countries in the region, can further stress immunization services. Even under routine circumstances, cold chain management, vaccine transportation, and human resource constraints can negatively affect vaccination coverage; these challenges might be experienced most acutely in countries with large rural populations.

The findings in this report are subject to at least five limitations. First, UNICEF/WHO coverage estimates are based on the best estimates of a combination of administrative data and survey data, each of which might be subject to overreporting or underreporting. Other factors potentially causing a discrepancy between rotavirus coverage and DTP coverage include the inability to compare the final dose of RV1 to the second dose of DTP, and the lack of data on coverage with the first dose of rotavirus vaccines. Second, although protocols for rotavirus surveillance are standardized across the entire network, there are a limited number of surveillance sites in each country; these might not be representative of pediatric diarrheal illness across the country and might provide an incomplete picture of impact. Third, immunization and surveillance data quality vary among countries. Fourth, not all sites have been able to conduct continuous rotavirus disease surveillance, and data were not included in these results if analysis criteria were not met. Finally, rotavirus surveillance data are not available for all countries before introduction, limiting the ability to assess vaccine impact in countries without vaccine preintroduction data or those that are not part of the ARSN.

Overall, substantial progress has been made in the introduction of rotavirus vaccine and surveillance for rotavirus disease in countries in the WHO African Region. In countries where rotavirus vaccine has been introduced, a substantial decline in the percentage of rotavirus-associated pediatric diarrhea hospitalizations was observed. As rotavirus vaccination coverage increases, an even greater decline might be expected; however, continuous surveillance is a critical component of measuring vaccine impact. Financial support from Gavi, the Vaccine Alliance, has played a key role in rotavirus vaccine introduction and rotavirus surveillance in the region ([@R10]). Nonetheless, Gavi support will not continue indefinitely; as their economies improve, countries will graduate from Gavi support and begin to finance the total cost of the vaccine. Maintaining surveillance for rotavirus disease will provide important data necessary to promoting continued investment in rotavirus vaccination. Rotavirus vaccination is a critical element in reducing child deaths from diarrhea and contributing to the improvement of child health globally.

###### Summary

What is already known about this topic?
---------------------------------------

Rotavirus is a leading cause of severe pediatric diarrhea worldwide, and a disproportionate number of deaths occur in countries in the World Health Organization (WHO) African Region. WHO recommends rotavirus vaccination for all infants worldwide.

What is added by this report?
-----------------------------

As of December 2016, 31 of 47 (66%) countries in the WHO African Region had introduced rotavirus vaccination into their national schedules. Among these countries, the overall coverage for the completed series of rotavirus vaccination was 77% in 2016. In 12 countries with available sentinel hospital surveillance data before and after rotavirus vaccine introduction, the proportion of pediatric diarrhea hospitalizations that were rotavirus-positive declined 33%, from 39% to 26%.

What are the implications for public health practice?
-----------------------------------------------------

Continued commitment to improving rotavirus vaccination coverage in the WHO African Region should contribute to reducing the morbidity and mortality associated with this disease. Maintaining and enhancing the existing surveillance network will be critical to the ability to measure vaccine impact.
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